Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Hypercalcemia : clinical diagnosis and management / / Marcella Donovan Walker, editor
| Hypercalcemia : clinical diagnosis and management / / Marcella Donovan Walker, editor |
| Pubbl/distr/stampa | Cham, Switzerland : , : Humana, , [2022] |
| Descrizione fisica | 1 online resource (257 pages) |
| Disciplina | 616.399 |
| Collana | Contemporary endocrinology |
| Soggetto topico | Hypercalcemia |
| ISBN |
9783030931827
9783030931810 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Series Editor's Foreword -- Preface -- Contents -- Contributors -- Chapter 1: Normal Regulation of Serum Calcium -- Introduction -- Calcium Distribution -- Calcium Distribution: Daily Homeostasis -- Calcium Distribution: Extracellular and Intracellular Calcium Distribution -- Calcium Distribution: Bone Is the Main Body Reservoir for Calcium -- Hormonal Calcium Regulation -- Parathyroid Hormone -- Vitamin D -- Calcitonin -- PTH-Related Peptide -- Phosphorus Regulation -- Fibroblast Growth Factor 23 (FGF23) -- Putting It All Together: The Feedback Mechanisms Responsible for Calcium Homeostasis -- Gastrointestinal System -- Kidneys -- References -- Chapter 2: Pathophysiology, Causes, and Clinical Manifestations of Hypercalcemia -- Introduction -- Calcium Homeostasis: Roles of the Skeleton, Intestine, and Kidney -- Skeleton -- Intestine -- Kidney -- Hormonal Regulation -- Symptoms and Signs of Hypercalcemia -- General -- Gastrointestinal -- Renal -- Neuropsychiatric -- Musculoskeletal -- Cardiovascular -- Physical Exam Findings -- Causes of Hypercalcemia -- Parathyroid Related -- Primary Hyperparathyroidism -- Lithium Therapy -- Familial Hypocalciuric Hypercalcemia -- Metaphyseal Chondrodysplasia -- PTH Therapy Related -- Malignancy Related -- Vitamin D Related -- Vitamin D Intoxication -- Increased 1,25(OH)2D -- Associated with High Bone Turnover -- Hyperthyroidism -- Immobilization -- Thiazides -- Vitamin A Intoxication -- Associated with Renal Failure -- Severe Secondary Hyperparathyroidism -- Aluminum Intoxication -- Milk-Alkali Syndrome -- Rhabdomyolysis -- Miscellaneous Causes and Medications -- References -- Chapter 3: Diagnostic Approach to the Adult Patient with Hypercalcemia -- Introduction and Epidemiology -- Normal Regulation of Serum Calcium -- Pathophysiology, Differential Diagnosis, and Overview of Causes of Hypercalcemia.
Diagnostic Approach -- Confirm Hypercalcemia -- History and Physical Examination: Symptoms and Signs -- Laboratory Testing -- PTH -- Parathyroid Hormone-Related Peptide and Other Testing for Malignancy -- Vitamin D Metabolites -- Other Tests and Timing of Tests -- Other Etiologies -- Pitfalls in Diagnosis and Other Considerations -- Assay Interference -- Effect of Renal Dysfunction on PTH and PTHrP Assays -- Benign Production of PTHrP -- Conclusion -- References -- Chapter 4: Diagnostic Approach and Treatment of the Pediatric Patient with Hypercalcemia -- Introduction -- General Considerations -- Hypercalcemic Disorders of Childhood -- Parathyroid Hormone (PTH) Excess -- Other Forms of PTH1R Activation -- Excessive Vitamin D Action -- Other Disorders of Excess Gastrointestinal Calcium Absorption -- Non-PTH, PTHrP, or Vitamin D-Mediated Excess Bone Mineral Resorption -- Diminished Bone Mineral Deposition -- Diminished Renal Excretion of Calcium -- Pathophysiology Unknown -- Diagnostic and Treatment Approach -- Conclusion -- References -- Chapter 5: General Management and Treatment of Acute and Chronic Hypercalcemia in Adults -- Introduction -- Pathophysiology, Metabolic Effects, and Clinical Manifestations of Hypercalcemia -- General Considerations in the Treatment of Hypercalcemia -- Indications for Treatment -- Therapy of Severe Hypercalcemia -- Fundamental Approach -- Intravenous Hydration with Isotonic Saline -- Salmon Calcitonin -- Intravenous Bisphosphonates -- Denosumab -- Glucocorticoids -- Renal Replacement Therapy -- Calcimimetics -- Prevention of Hypercalcemia Recurrence -- Disease-Specific Approaches to Management of Hypercalcemia -- Summary -- References -- Chapter 6: Primary Hyperparathyroidism -- Introduction -- Risk Factors, Pathology, and Anatomical Location -- Epidemiology -- Diagnosis and Differential Diagnosis. Pathophysiology of Hypercalcemia in PHPT -- Clinical Presentation: Asymptomatic Versus Symptomatic PHPT -- Target Organs: Skeleton -- Bone Mineral Densitometry and Other Imaging Modalities -- Fractures -- Target Organs: The Kidney -- Nonclassical Organ Involvement -- Evaluation -- Natural History: Observational Experience -- After Surgery -- Without Surgery -- Natural History: Randomized Controlled Trials -- Who Should Be Recommended to Have Parathyroid Surgery? Guidelines for Surgical Intervention -- Surgery -- Preoperative Localization of Hyperfunctioning Parathyroid Tissue -- Parathyroidectomy -- Nonsurgical Management -- General Measures -- Pharmacological Approaches to PHPT -- Summary -- References -- Chapter 7: Genetic Causes of Primary Hyperparathyroidism -- Introduction -- Familial Hypocalciuric Hypercalcemia Syndrome -- Neonatal Severe Primary Hyperparathyroidism -- Multiple Endocrine Neoplasia Type 1 -- Multiple Endocrine Neoplasia Type 4 -- Multiple Endocrine Neoplasia Type 2A -- Hyperparathyroidism-Jaw Tumor Syndrome -- Familial Isolated Primary Hyperparathyroidism -- Sporadic Primary Hyperparathyroidism -- References -- Chapter 8: Familial Hypocalciuric Hypercalcemia and Disorders of the Calcium-Sensing Receptor -- Epidemiology -- Pathophysiology -- Etiology -- Clinical Presentation -- Diagnosis -- Management/Treatment -- References -- Chapter 9: Overview of Hypercalcemia of Malignancy and Humoral Hypercalcemia of Malignancy -- Overview of the Mechanisms of Hypercalcemia of Malignancy -- Humoral Hypercalcemia of Malignancy: History, Pathophysiology, and Detection -- Rare Causes of Hypercalcemia of Malignancy: HTLV-1/ATLL and Non-parathyroid Tumors -- Treatment of PTHrP-Mediated Hypercalcemia of Malignancy -- Conclusions -- References -- Chapter 10: Myeloma-Related Hypercalcemia and Bone Disease -- Introduction. Epidemiology and Diagnosis -- Pathophysiology of Bone Disease in Multiple Myeloma -- Clinical Presentation of Bone Disease in Multiple Myeloma -- Effect of Myeloma Bone Disease on Survival of Patients with Multiple Myeloma -- Management of Myeloma Bone Disease -- Summary -- References -- Chapter 11: Hypercalcemia Due to Malignancy-Related Production of 1,25-Dihydroxyvitamin D -- Introduction and Epidemiology -- Associated Malignancies -- Mechanism of 1,25-Dihydroxyvitamin D Production -- Clinical and Biochemical Presentation -- Treatment -- Summary -- References -- Chapter 12: Vitamin D Intoxication -- Overview of Vitamin D Metabolism -- Measurement of Vitamin D/Epidemiology of Vitamin D Intoxication -- Pathophysiology of Hypercalcemia Related to Vitamin D Intoxication -- Presentation -- Treatment for Vitamin D Intoxication -- Conclusion -- References -- Chapter 13: Benign 1,25-Dihydroxyvitamin D-Mediated Hypercalcemia -- Introduction -- Vitamin D Production, Metabolism, and Actions -- Signs and Symptoms -- Causes of 1,25(OH)2D-Mediated Hypercalcemia -- Congenital Conditions -- Granulomatous Diseases -- Evaluation -- Management -- References -- Chapter 14: Medication-Induced Hypercalcemia -- Introduction -- Specific Medications Associated with Hypercalcemia -- Calcium -- Vitamin D -- Vitamin A -- Thiazide Diuretics -- Lithium -- Parenteral Nutrition -- Theophylline -- Foscarnet -- Growth Hormone -- Omeprazole -- Aromatase Inhibitors -- Parathyroid Hormone -- Denosumab -- Summary -- References -- Chapter 15: Non-parathyroid Hormone-Mediated Endocrine Causes of Hypercalcemia -- Epidemiology -- Causes -- Thyrotoxicosis -- Pathophysiological Mechanism -- Presentation -- Clinical and Biochemical Patterns -- Diagnostic Testing -- Treatment -- Pheochromocytoma -- Pathophysiological Mechanism -- Presentation -- Clinical and Biochemical Patterns. Diagnostic Testing -- Treatment -- Adrenal Insufficiency -- Pathophysiological Mechanism -- Presentation -- Clinical and Biochemical Patterns -- Diagnostic Testing -- Treatment -- Acromegaly -- Pathophysiological Mechanism -- Presentation -- Clinical and Biochemical Patterns -- Diagnostic Testing -- Treatment -- References -- Chapter 16: Rare and Other Causes of Hypercalcemia -- Immobilization -- Rhabdomyolysis -- Paget's Disease of the Bone -- Advanced Chronic Liver Disease -- Paraffin Granulomatosis -- PTHrP-Associated Hypercalcemia in Benign Disease -- Conclusions -- References -- Index. |
| Record Nr. | UNINA-9910544863103321 |
| Cham, Switzerland : , : Humana, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Hypercalcemia : Clinical Diagnosis and Management / Marcella Donovan Walker editor
| Hypercalcemia : Clinical Diagnosis and Management / Marcella Donovan Walker editor |
| Pubbl/distr/stampa | Cham, : Humana, 2022 |
| Descrizione fisica | XV, 251 p. ; 24 cm |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNICAMPANIA-VAN0266316 |
| Cham, : Humana, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Vanvitelli | ||
| ||
Hypertension in High Risk African Americans : Current Concepts, Evidence-based Therapeutics and Future Considerations / Keith C. Ferdinand editor
| Hypertension in High Risk African Americans : Current Concepts, Evidence-based Therapeutics and Future Considerations / Keith C. Ferdinand editor |
| Pubbl/distr/stampa | New York, : Humana, 2015 |
| Descrizione fisica | xi, 277 p. ; 24 cm |
| ISBN | 978-14-939200-9-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNICAMPANIA-VAN0132461 |
| New York, : Humana, 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Vanvitelli | ||
| ||
I quaderni della Mediateca delle Marche
| I quaderni della Mediateca delle Marche |
| Pubbl/distr/stampa | Ancona : Humana : [poi] Mediateca delle Marche |
| Descrizione fisica | volumi ; 21 cm |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | ita |
| Note periodicità | Bimestrale |
| Record Nr. | UNISA-990002828800203316 |
| Ancona : Humana : [poi] Mediateca delle Marche | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Lipoprotein(a) / / edited by Karam Kostner, Gerhard M. Kostner, and Peter P. Toth
| Lipoprotein(a) / / edited by Karam Kostner, Gerhard M. Kostner, and Peter P. Toth |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Humana, , [2023] |
| Descrizione fisica | 1 online resource (446 pages) |
| Disciplina | 371 |
| Collana | Contemporary cardiology (Totowa, N.J.) |
| Soggetto topico | Lipoprotein A |
| ISBN | 3-031-24575-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 60 years of Lp(a) research-From Ouchterlonys double diffusion to a significant risk factor for CHD -- Lp(a) structure and composition -- Genetics of Lipoprotein(a) -- Lp(a) metabolism -- Contemporary aspects of Lp(a) metabolism and therapies based on tracer kinetic methods -- Role of Proprotein Convertase Subtilisin Kexin type 9 in Lipoprotein(a) Metabolism -- The Role of Cell Surface Receptors in Lp(a) Metabolism -- Physiological Roles And Functions Of Lipoprotein(a) -- The role of Lp(a) in Atherosclerosis: An overview -- Role of macrophages in Lp(a) pathophysiology -- Thrombosis, Inflammation and Lipoprotein(a): Clinical Implications -- The role of the kidney in Lp(a) physiology and pathophysiology -- Lp(a) as a cardiovascular risk factor -- Lp(a) and aortic valve stenosis, stroke, and other non-coronary cardiovascular diseases -- Lp(a) in cardiovascular disease: Evidence from Large Epidemiological Studies -- Lipoprotein(A) And Immunity -- When to measure Lp(a) -- Measurement of Lipoprotein (a) in the Clinical Laboratory -- Standardization of analytical methods for the measurement of Lipoprotein(a): bridging past and future initiatives -- Establishing an SI-traceable Reference Measurement System for Lp(a), based on Quantitative Protein Mass Spectrometry and Molar Units -- Compounds that impact Lp(a) concentrations -- Antisense oligonucleotide therapy to treat elevated lipoprotein(a) -- Lipoprotein apheresis for reduction of Lipoprotein(a) -- Elevated Lp(a) - Why Should I Test For It, If I Cannot Treat It? A Patient’s Perspective -- Burning unanswered questions Therapy. |
| Record Nr. | UNINA-9910678261303321 |
| Cham, Switzerland : , : Humana, , [2023] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lipoprotein(a) / Karam Kostner, Gerhard M. Kostner, Peter P. Toth editors
| Lipoprotein(a) / Karam Kostner, Gerhard M. Kostner, Peter P. Toth editors |
| Pubbl/distr/stampa | Cham, : Humana, 2023 |
| Descrizione fisica | XVII, 443 p. ; 24 cm |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNICAMPANIA-VAN0274026 |
| Cham, : Humana, 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Vanvitelli | ||
| ||
Lipoproteins in Diabetes Mellitus / Alicia J. Jenkins, Peter P. Toth editors
| Lipoproteins in Diabetes Mellitus / Alicia J. Jenkins, Peter P. Toth editors |
| Edizione | [2. ed] |
| Pubbl/distr/stampa | Cham, : Humana, 2023 |
| Descrizione fisica | XX, 926 p. ; 24 cm |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNICAMPANIA-VAN0274033 |
| Cham, : Humana, 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Vanvitelli | ||
| ||
Liquid Biopsy in Cancer Patients : The Hand Lens for Tumor Evolution / Antonio Russo, Antonio Giordano, Christian Rolfo editors
| Liquid Biopsy in Cancer Patients : The Hand Lens for Tumor Evolution / Antonio Russo, Antonio Giordano, Christian Rolfo editors |
| Pubbl/distr/stampa | Cham, : Humana, 2017 |
| Descrizione fisica | xi, 214 p. ; 24 cm |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNICAMPANIA-VAN0131398 |
| Cham, : Humana, 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Vanvitelli | ||
| ||
Lung Cancer : A Comprehensive Guide for the Clinician / Christina R. MacRosty, M. Patricia Rivera editors
| Lung Cancer : A Comprehensive Guide for the Clinician / Christina R. MacRosty, M. Patricia Rivera editors |
| Pubbl/distr/stampa | Cham, : Humana, 2023 |
| Descrizione fisica | XIII, 304 p. ; 24 cm |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNICAMPANIA-VAN0274065 |
| Cham, : Humana, 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Vanvitelli | ||
| ||
Lung cancer : new understandings and therapies / / Anne C. Chiang, Roy S. Herbst, editors
| Lung cancer : new understandings and therapies / / Anne C. Chiang, Roy S. Herbst, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Humana, , [2021] |
| Descrizione fisica | 1 online resource (263 pages) |
| Disciplina | 616.99424 |
| Collana | Current cancer research |
| Soggetto topico |
Lungs - Cancer
Lung Neoplasms - therapy Càncer de pulmó Quimioteràpia del càncer Radioteràpia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-74028-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- Chapter 1: Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- 1 Introduction -- 2 The Tumor Compartment -- 2.1 Immune Inhibitory Signals -- 2.2 Immune Suppressive Cytokines -- 2.3 Antigen Presentation Machinery Alterations -- 2.4 Altered Intracellular Signaling and Differentiation -- 3 The Stromal Compartment -- 3.1 Immune Cells in the Stroma -- 3.1.1 Adaptive Immune Cells: T Lymphocytes -- 3.1.2 Adaptive Immune Cells: B Lymphocytes -- 3.1.3 Innate Immune Cells: NK Cells -- 3.1.4 Innate Immune Cells: Myeloid Cells -- 3.2 Non-immune Cells in the Stroma -- 3.2.1 Non-immune Cells in the Stroma: Cancer Associated Fibroblasts (CAFs) -- 3.2.2 Non-immune Cells in the Stroma: Vascular Cells -- 3.3 Non-Cellular Elements of the TME: The Extracellular Matrix (ECM) -- 4 Biomarkers -- 4.1 Validated Biomarkers in the Tumor -- 4.1.1 PD-L1 Expression -- 4.1.2 Oncogenic Drivers -- 4.1.3 Tumor Mutational Burden -- 4.2 Validated Biomarkers in the Stroma -- 4.2.1 Tumor Infiltrating Lymphocytes (TILs) -- 4.2.2 T-Cell RNA Signatures -- 4.2.3 Developing Biomarkers -- Interferon Gamma Response Pathway -- Beta-2-Microglobulin Alterations -- DNA Sensing Alterations: LKB1 -- FBXW7 -- TGFß Pathway -- Activation of Alternative Immune Pathways -- Microbiome -- Immune Heterogeneity -- 5 Conclusions -- References -- Chapter 2: Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail? -- 1 Introduction -- 2 Definition of TMB and TMB Assessment Methods -- 3 TMB and Association with Response to ICIs -- 3.1 Pembrolizumab -- 3.2 Nivolumab -- 3.3 Atezolizumab -- 3.4 Durvalumab, Durvalumab Plus Tremelimumab -- 3.5 Nivolumab Plus Ipilimumab -- 3.6 Real-World Analyses -- 4 Efficacy of TMB as a Predictive Biomarker -- 5 Pragmatic Limitations -- 5.1 TMB Standardization -- 5.2 Feasibility of Assessing TMB in Routine Clinical Practice.
6 Biology Underlying the Response Association -- 7 Integrating TMB with Other Biomarkers of ICI Response -- 8 Conclusion -- References -- Chapter 3: Liquid Biopsies: New Technology and Evidence -- 1 Introduction -- 2 Circulating Tumor DNA -- 3 Initial Molecular Profiling in NSCLC -- 4 Detection of the Mechanism of Acquired Resistant to Targeted Therapy -- 5 Detection of Minimal Residual Disease -- 6 Small Cell Lung Cancer -- 7 Extracellular Vesicles -- 8 Circulating Tumor Cells -- 9 Conclusion -- References -- Chapter 4: Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- 1 Clinical Activity of Osimertinib -- 2 Activity in CNS and Leptomeningeal Disease -- 3 Osimertinib in the Adjuvant Setting -- 4 Resistance to Osimertinib -- 5 Conclusion -- References -- Chapter 5: Immune Therapy: What Can We Learn From Acquired Resistance? -- 1 Introduction -- 2 Defining Acquired Resistance -- 2.1 Classification Based on Initial Response -- 2.2 Acquired Resistance Versus Off-Therapy Progression -- 3 Clinical Observations in Patients with Advanced NSCLC and Acquired Resistance to PD-1 Axis Inhibitors -- 4 Concepts in the Management of Acquired Resistance to PD-1 Axis Inhibitors in Advanced NSCLC -- 4.1 Local Therapy -- 4.2 Resume/Re-Challenge with PD-1 Axis Inhibitor Therapy -- 4.3 PD-1 Axis Inhibitor Combinations -- 4.3.1 PD-1 Axis Inhibitors + CTLA-4 Inhibitors -- 4.3.2 Novel Combination Strategies for PD-1 Axis Inhibitor Relapsed/Refractory NSCLC -- PD-1 Axis Inhibitor + Interleukin Receptor Agonist -- PD-1 Axis Inhibitor + Histone Deacetylase Inhibitors (HDACi) -- PD-1 Axis Inhibitor + Adenosine A2A Receptor Antagonists -- PD-1 Axis Inhibitor + Sitravatinib -- PD-1 Axis Inhibitor + Anti-TIM-3 -- Retinoic Acid Receptor-Related Orphan Receptor γ (RORγ) +/− PD-1 Axis Inhibitor. 4.4 Chemotherapy Sensitization -- 5 Mechanisms Mediating Acquired Resistance to PD-1 Axis Inhibitors in NSCLC -- 5.1 Acquired Neoantigen Loss -- 5.2 Acquired Antigen Processing and Presentation Defects -- 6 Uncovering Mechanisms of IO-Acquired Resistance in Other Tumor Types -- 6.1 Acquired Defects in Interferon-Gamma (IFN- γ) Signaling and Antigen Presentation -- 6.2 Immune-Suppressive Changes in the Tumor Microenvironment -- 6.3 PTEN Loss -- 6.4 Novel Experimental Discoveries -- 6.5 Conclusions and Future Visions -- References -- Chapter 6: Management of Brain Metastases -- 1 Introduction -- 2 Local Treatments for Brain Metastases: The Historical Standard of Care -- 3 Challenges in the Use of Systemic Treatment for Brain Metastases -- 4 Systemic Therapies for Brain Metastases in NSCLC -- 4.1 Chemotherapy -- 4.2 Targeted Therapies -- 4.2.1 EGFR Mutations -- 4.2.2 ALK Rearrangements -- 4.2.3 Other Driver Mutations (ROS1, RET, BRAF, MET, NTRK) -- 4.3 Immunotherapy - Checkpoint Inhibitors -- 5 Conclusions -- References -- Chapter 7: Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- 1 Introduction -- 1.1 Clinical Scenario -- 1.2 Mechanism of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- 1.3 Incidence of IRAEs by Agent and in Combination -- 1.4 Biomarkers to Identify Patients at Risk for Developing IRAEs -- 2 Management of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors (ICPIs) -- 3 Organ Specific Immune-Related Adverse Events -- 3.1 Dermatologic -- 3.2 Gastrointestinal -- 3.3 Pulmonary -- 3.4 Endocrine -- 3.5 Hepatic -- 3.6 Renal -- 3.7 Cardiac -- 3.8 Neurologic -- 3.9 Musculoskeletal-Rheumatologic -- 3.10 Ocular -- 3.11 Hematologic -- 4 Summary -- References -- Chapter 8: Therapeutic Advances in Small Cell Lung Cancer Management -- 1 Introduction. 2 Limited Stage Small Cell Lung Cancer -- 2.1 Surgery for Limited Stage Small Cell Lung Cancer -- 2.2 Chemoradiation for Limited Stage Small Cell Lung Cancer -- 2.3 Checkpoint Inhibitors in Limited Stage Small Cell Lung Cancer -- 2.4 Prophylactic Cranial Radiation for Limited Stage Small Cell Lung Cancer -- 2.5 Surveillance After Initial Management of Limited Stage Small Cell Lung Cancer -- 3 Extensive Stage Small Cell Lung Cancer -- 3.1 Thoracic Irradiation as Consolidation Therapy -- 3.2 Prophylactic Cranial Radiation in Extensive Stage Small Cell Lung Cancer -- 4 Brain Metastasis -- 5 Treatment of Refractory and Relapsed Small Cell Lung Cancer -- 5.1 Checkpoint Inhibitor Therapy for Relapsed Disease -- 5.2 Chemotherapy for Relapsed Disease -- 5.3 Beyond the Second Line -- 6 Novel Treatments -- 6.1 DNA Repair -- 6.2 MYC Gene Family -- 6.3 Epigenetics -- 6.4 Other Approaches -- 7 Conclusion -- References -- Chapter 9: Small Cell Lung Cancer: Biology Advances -- 1 Introduction -- 2 Identifying Therapeutic Targets in SCLC -- 2.1 DNA Damage Response (DDR) Proteins -- 2.2 DDR Inhibition and Immunotherapy -- 2.3 MYC -- 2.4 Targets in Developmental Pathways -- 2.5 BCL2 -- 2.6 Epigenetic Inhibitors -- 3 Immunotherapy: Recent Approvals, Biomarkers and Novel Combinations -- 4 A New Classification System: SCLC Subtypes Based on Dominant Gene Expression Profile -- 5 Conclusions -- References -- Chapter 10: Immunotherapy and Radiotherapy: New Strategies -- 1 Introduction -- 2 Radiotherapy as In Situ Vaccine -- 2.1 Principles of Vaccination as Applied to NSCLC -- 2.2 Radiotherapy as Both Antigen and Adjuvant -- 3 Radiotherapy and the Innate Immune System -- 3.1 Immunogenic Cell Death -- 3.2 DNA Damage Machinery and Pattern Recognition Receptors: An Emerging Overlap -- 3.3 Recognition of DNA Damage with cGAS/STING -- 3.4 Recognition of DNA Damage with AIM2. 3.5 RAD51 at the Intersection of the DNA Damage Response and Innate Immunity -- 3.6 Radiotherapy and RNA Sensing: RIG-I -- 3.7 Type I IFN in Acute and Chronic Settings -- 3.8 Immunostimulatory Effects of Acute Type I IFN in Cancer -- 3.9 Immunosuppressive Effects of Chronic Type I IFN in Cancer -- 4 Radiotherapy and the Adaptive Immune System -- 4.1 Priming of the Adaptive Immune System -- 4.2 The Importance of Cross-Presentation in the Anti-tumoral Response -- 4.3 Radiotherapy and Immunological Memory -- 4.4 T Cell Exhaustion within the Tumor Microenvironment -- 4.5 Checkpoint Inhibition and Radiotherapy -- 5 Maximizing the Clinical Utility of Radiotherapy in an Era of Checkpoint Inhibition: New Strategies -- 5.1 Rational Treatment Design -- 5.2 Choice of Target -- 5.3 Timing -- 5.4 Dose and Fractionation -- 6 Conclusions -- References -- Chapter 11: Ultimate Precision: Targeting Cancer But Not Normal Self-Replication -- 1 Introduction -- 2 Replication and Lineage-Differentiation Are Linked -- 3 Dis-Engaging Replication from Advances Along a Lineage -- 4 The Importance of Reconciling These Different Models -- 5 Cell-of-Origin Versus Cell-of-Transformation -- 6 Master Transcription Factor Alterations in Cancer Cells -- 7 Targeting Cancer, But Not Normal, Self-Replication -- 8 Conclusion -- References -- Index. |
| Record Nr. | UNINA-9910502622503321 |
| Cham, Switzerland : , : Humana, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
